The emergence of the deadly zoonotic SARS-CoV-2 betacoronavirus responsible of Covid-19 pandemic in human has mobilized the scientific and medical communities to develop strategies against virus diffusion and death all over the world. The expertise gained by PAVAL Lab., in the fight against chronic infectious diseases was rapidly adapted to SARS-CoV-2 acute infectious disease to develop an innovative therapy and a vaccine. The novel therapy is evaluated in PAVAL Lab, while the vaccine prototypes are designed and tested by a joined work of PAVAL Lab., and the recently created Start-up company AIOVA. This company uses the patented PAVAL Lab., lentiDNA platform to develop and license lentiDNA prototype vaccine.

©2020 par Pathogénèse et Vaccinations Lentivirales. Créé avec